Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DOS · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DOS (Docetaxel, Oxaliplatin and S-1) | EXPERIMENTAL | Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period) |
| Name | Type | Description |
|---|---|---|
| DOS (Docetaxel, Oxaliplatin and S-1) | DRUG | Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period) |
Inclusion Criteria: * Histologically confirmed gastric adenocarcinoma, initially diagnosed or recurred * Unresectable, locally advanced or metastatic * At least one uni-dimensional measurable lesion by RECIST criteria * Age 18 to 70 years old * ECOG performance status ≤2 * Estimated life expectancy...